Targeting Non-Replicating Mycobacterium tuberculosis and Latent Infection: Alternatives and Perspectives (Mini-Review).
Int J Mol Sci
; 22(24)2021 Dec 10.
Article
en En
| MEDLINE
| ID: mdl-34948114
ABSTRACT
Latent tuberculosis infection (LTBI) represents a major challenge to curing TB disease. Current guidelines for LTBI management include only three older drugs and their combinations-isoniazid and rifamycins (rifampicin and rifapentine). These available control strategies have little impact on latent TB elimination, and new specific therapeutics are urgently needed. In the present mini-review, we highlight some of the alternatives that may potentially be included in LTBI treatment recommendations and a list of early-stage prospective small molecules that act on drug targets specific for Mycobacterium tuberculosis latency.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Rifampin
/
Tuberculosis Latente
/
Isoniazida
Tipo de estudio:
Guideline
Límite:
Humans
Idioma:
En
Año:
2021
Tipo del documento:
Article